Renal damage in HIV infection

References

  1. Белозеров Е. С., Буланьков Ю. И. ВИЧ-инфекция. Элиста: АПП "Джангар"; 2006.
  2. Gupta S. К., Eustace J. A., Winston J. A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America . Clin. Infect. Dis. 2005; 40: 1559-1585.
  3. Gupta S. K., Mamlin B. W., Johnson C. S. et al. Prevalence of proteinuria and development of chronic kidney disease in HIV-infected patients. Clin. Nephrol. 2004; 61: 1-6.
  4. Szczech L. A., Gupta S. K., Habash R. et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004; 66: 1145-1152.
  5. Röling J., Schmid H., Fischereder M. et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin. Infect. Dis. 2006; 42: 1488-1495.
  6. Kimmel P. L., Barisoni L., Kopp J. B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 2003; 139: 214-227.
  7. Winston J. A., Klotman M. E., Klotman P. E. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int. 1999; 55: 1036-1040.
  8. Atta M. G., Choi M. J., Longenecker J. С. et. al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am. J. Med. 2005; 118: 1288.
  9. Rao T. K., Filippone E. J., Nicastri A. D. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1984; 310 (11): 669- 673.
  10. D'Agati V., Appel G. B. HIV infection and the kidney. J. Am. Soc. Nephrol. 1997; 8: 138-152.
  11. United States Renal Data System 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; 2003.
  12. Lucas G. M., Eustace J. A., Sozio S. et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18 (3): 541-546.
  13. Abbott K. C., Hypolite L., Welch P. G., Agodoa L. Y. Human immunodeficiency virus/acquired immunodeficiency syndromeassociated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the prehighly active antiretroviral therapy era. J. Nephrol. 2001; 14 (5): 377-383.
  14. Woolley I. J., Kalayjian R., Valdez H. et al. HIV nephropathy and the Duffy antigen/receptor for Chemokines in African Americans. J. Nephrol. 2001; 14: 384-387.
  15. Pardo V., Meneses R., Ossa L. et al. AIDS-related glomerulopathy: occurrence in specific risk groups. Kidney Int. 1987; 31 (5): 1167-1173.
  16. Monahan M., Tanji N., Klotman P. E. HIV-associated nephropathy: an urban epidemic. Semin. Nephrol. 2001; 21: 394- 402.
  17. Laradi A., Mallet A., Beaufils H. et al. HIV-associated nephropathy: outcome and prognosis factors. J. Am. Soc. Nephrol. 1998; 9: 2327-2335.
  18. Bruggeman L. A., Dikman S., Meng С. et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J. Clin. Invest. 1997; 100 (1): 84-92.
  19. Winston J. A., Bruggeman L. A., Ross M. D. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 2001; 344 (26): 1979- 1984.
  20. Marras D., Bruggeman L. A., Gao F. et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat. Med. 2002; 8 (5): 522-526.
  21. Han T. M., Naicker S., Ramdial P. K. et al. A cross-sectional study of HIV-seropozitive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006; 69 (12): 2243- 2250.
  22. Ross M. J., Bruggeman L. A., Wilson P. D., Klotman P. E. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2001; 12: 2645-2651.
  23. Husain M., Gusella G. L., Klotman M. E. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 2002; 13 (7): 1806-1815.
  24. Ting-chi L., Ross M. HIV-associated nephropathy: a brief review. Mount Sinai J. Med. 2005; 75 (3): 193-199.
  25. Ahmed S., Siddiqui R. K., Siddiqui A. K. et al. HIV associated thrombotic microangiopathy. Postgrad. Med. J. 2002; 78: 520-524.
  26. Mientjes G., van Amerijden E., Mulder J. W. et al. Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men. Br. J. Haematol. 1992; 82: 615-619.
  27. Sutor G. C., Schmidt R. E., Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of literature. Infection. 1999; 27: 12-15.
  28. Vyakarnam A., Meatar P., Meager A. et al. Altered production of tumor necrosis factor alpha and beta and interferon gamma by HIV-infected individuals. Clin. Exp. Immunol. 1991; 84: 109-115.
  29. Sahud M. A., Clater S., Liu L. et al. von Willenrad factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br. J. Haematol. 2002; 116: 909-911.
  30. Bell W. R., Chulay J. D., Feinberg J. E. Manifestations resembeling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76: 369-380.
  31. Weiner N. J., Goodman J. W., Kimmel P. L. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int. 2003; 63: 1618-1631.
  32. Kimmel P. L., Barisoni L., Kopp J. B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 2003; 139: 214-227.
  33. Horvath J., Raffanti S. P. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin. Infect. Dis. 1994; 18 (3): 339-347.
  34. Beaufils H., Jouanneau C., Katlama C. et al. HIV-associated IgA nephropathy: a post-mortem study. Nephrol. Dial. Transplant. 995; 10: 35-38.
  35. Nochy D., Glotz D., Dosquet P. et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol. Dial. Transplant. 1993; 8: 11-19.
  36. Humphreys M. H. Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int. 1995; 48: 311.
  37. Kimmel P. L., Phillips Т. М., Ferreira-Centeno A. et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N. Engl. J. Med. 1992; 327: 702-706.
  38. Haas M., Kaul S., Eustace J. A. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinocopathological study of 14 cases. Kidney Int. 2005; 67: 1381- 1390.
  39. Franceschini N., Napravnik S., Eron J. J. et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005; 67: 1526-1531.
  40. Dong B. J., Rodriguez R. A., Goldschmidt R. H. Sulfadiazine-induced crystalluria and renal failure in a patient with AIDS. J. Am. Board Fam. Pract. 1999; 12 (3): 243-248.
  41. Berns J. S., Cohen R. M., Stumacher R. J., Rudnick M. R. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J. Am. Soc. Nephrol. 1991; 1 (9): 1061-1080.
  42. Peraldi M. N., Maslo C., Akposso K. et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol. Dial. Transplant. 1999; 14: 1578-1585.
  43. Betjes M. G., Verhagen D. W. Stable improvement of renal function after initiation of highly active anti-retroviral therapy in patients with HIV-1-associated nephropathy. Nephrol. Dial. Transplant. 2002; 17: 1836-1839.
  44. Szczech L. A., Edwards L. J., Sanders L. L. et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin. Nephrol. 2002; 57: 336-341.
  45. Murphy M. D., O'Hearn M., Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin. Infect. Dis. 2003; 36: 1082-1085.
  46. Daugas E., Rougier J. P., Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005; 67: 393-403.
  47. Barbour T. D., Furlong Т. J., Finlayson R. J. Efavirenz-associated podocyte damage. AIDS 2007; 21: 257-258.
  48. Wei A., Burns G. C., Williams B. A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003; 64 (4): 1462-1471.
  49. Eustace J. A., Nuermberger E., Choi M. et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000; 58 (3): 1253-1260.
  50. Tabechian D., Pattanaik D., Suresh U. et al. Lupus-like nephritis in an HIV-positive patient: report of a case and review of the literature. Clin. Nephrol. 2003; 60: 187-194.

Copyright (c) 2008 Yushchuk N.D., Volgina G.V., Martynov Y.V., Gadzhikulieva M.M., Kocharyan K.A., Yuschuk N.D., Volgina G.V., Martynov Y.V., Gadzhikulieva M.M., Kocharyan K.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies